Philippe Brantegem - Iteos Therapeutics Executive Resources
| ITOS Stock | USD 8.24 0.08 0.96% |
Executive
Philippe Brantegem is Executive Resources of Iteos Therapeutics
| Address | 321 Arsenal Street, Watertown, MA, United States, 02472 |
| Phone | 339 217 0161 |
| Web | https://www.iteostherapeutics.com |
Iteos Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1304) % which means that it has lost $0.1304 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1972) %, meaning that it created substantial loss on money invested by shareholders. Iteos Therapeutics' management efficiency ratios could be used to measure how well Iteos Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.18 in 2024. Return On Capital Employed is likely to drop to -0.25 in 2024. At this time, Iteos Therapeutics' Net Tangible Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 122.8 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 3.5 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| MD FACC | Design Therapeutics | 55 | |
| Leiden MBA | Tscan Therapeutics | N/A | |
| Farah Anwar | Sana Biotechnology | N/A | |
| Caroline MD | Apellis Pharmaceuticals | 57 | |
| JD Esq | Acumen Pharmaceuticals | 53 | |
| Nicolas Mosimann | MoonLake Immunotherapeutics | N/A | |
| Gina JD | Amylyx Pharmaceuticals | 53 | |
| Melita Jung | Terns Pharmaceuticals | 47 | |
| JD Esq | Kymera Therapeutics | 65 | |
| Miriam Mason | Annexon | N/A | |
| Jim Murray | Tscan Therapeutics | N/A | |
| Christina Rossi | Blueprint Medicines Corp | 47 | |
| Jeffrey Eisele | Apellis Pharmaceuticals | 62 | |
| Ariel Hurley | Blueprint Medicines Corp | 50 | |
| Robyn MA | Acumen Pharmaceuticals | N/A | |
| Mustapha Parekh | Design Therapeutics | N/A | |
| David Acheson | Apellis Pharmaceuticals | N/A | |
| Shikhar MBA | Annexon | N/A | |
| Emil MD | Terns Pharmaceuticals | 44 | |
| Christina MBA | Blueprint Medicines Corp | 48 | |
| Debra DursoBumpus | Blueprint Medicines Corp | 54 | |
Management Performance
| Return On Equity | -0.2 | ||||
| Return On Asset | -0.13 |
Iteos Therapeutics Leadership Team
Elected by the shareholders, the Iteos Therapeutics' board of directors comprises two types of representatives: Iteos Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Iteos. The board's role is to monitor Iteos Therapeutics' management team and ensure that shareholders' interests are well served. Iteos Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Iteos Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Matthew Gall, Chief Officer | ||
| Matthew MBA, Chief Officer | ||
| Ryan Baker, Head Relations | ||
| Phillipe Brantegem, VicePresident Resources | ||
| Joanne MD, Chief Officer | ||
| Adi Osovsky, Executive Legal | ||
| Michel Detheux, CEO President | ||
| Yvonne McGrath, Chief Officer | ||
| FACP MD, Interim Officer | ||
| David MD, Chief Officer | ||
| Philippe Brantegem, Executive Resources |
Iteos Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Iteos Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.2 | ||||
| Return On Asset | -0.13 | ||||
| Operating Margin | (4.17) % | ||||
| Current Valuation | (179.22 M) | ||||
| Shares Outstanding | 36.53 M | ||||
| Shares Owned By Insiders | 0.71 % | ||||
| Shares Owned By Institutions | 99.29 % | ||||
| Number Of Shares Shorted | 3.12 M | ||||
| Price To Earning | 50.50 X | ||||
| Price To Book | 0.48 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Iteos Stock Analysis
When running Iteos Therapeutics' price analysis, check to measure Iteos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iteos Therapeutics is operating at the current time. Most of Iteos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Iteos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iteos Therapeutics' price. Additionally, you may evaluate how the addition of Iteos Therapeutics to your portfolios can decrease your overall portfolio volatility.